Types of Communication Devices for ALS Patients | What Works

ALS communication devices for patients range from low-tech boards and free apps to dedicated SGDs like the Tobii Dynavox I-Series with eye-gaze.

When ALS steals the ability to speak, finding a working way to communicate becomes urgent. The three tiers of communication devices for ALS patients — low-tech tools, mid-tech apps, and high-tech speech-generating devices — each serve a different stage of the disease and a different budget. The choice depends on remaining motor function, insurance coverage, and how fast the disease is progressing, so knowing what exists before an evaluation speeds up the whole process. A referral for an AAC evaluation is the standard of care once speaking rates drop to 125 words per minute or less, making early awareness critical.

Communication Devices for ALS Patients: Options That Work at Every Stage

ALS communication devices fall into three tiers, each suited to a different phase of the disease. Low-tech tools like alphabet boards work at any stage and cost under $200. Mid-tech AAC apps run on tablets you may already own, with options from free downloads to paid apps like Proloquo2Go at $250. High-tech dedicated speech-generating devices (SGDs) from Tobii Dynavox and PRC-Saltillo cost between $3,000 and $15,000 but support eye-gaze and head-mouse access as motor function declines. Emerging brain-computer interfaces are in clinical trials but not yet commercially available.

The right device depends on what the patient can do physically today — and what they will be able to do six months from now. A device with only touch access fails as hand strength disappears. The best choice supports multiple access methods so the same unit transitions from hand control to head tracking to eye-gaze without requiring a new purchase.

Low-Tech Communication Tools Worth Knowing About

Low-tech options require no power, no prescription, and no training. Alphabet boards where the user spells by gazing, LCD writing tablets like the Boogie Board, and simple signaling devices such as bells or buzzers cost between $30 and $200. These are often the fastest way to start communicating while a formal AAC evaluation is scheduled.

Partner-assisted scanning is another low-tech method that works when the patient has minimal voluntary movement. The caregiver points to letters or words on a board, and the patient signals a switch with a sound, blink, or finger twitch. This approach requires no equipment beyond the board and a reliable signal from the patient. The Les Turner ALS Foundation provides printable communication boards on its site.

Mid-Tech AAC Apps for Tablets

If the family already owns an iPad or Android tablet, AAC apps provide robust communication at a fraction of the cost of a dedicated device. Proloquo2Go ($250) is the most established paid option, offering dynamic vocabulary pages and natural-sounding voices. Free alternatives like LetMeTalk and CBoard cover the basics for users who need simple picture-to-speech or text-to-speech functionality.

These apps work through touch or external joystick access. They lack the eye-gaze and head-mouse support that dedicated SGDs offer, so they work best for patients who still have reliable hand or finger control. When hand strength fades, the tablet-based setup may no longer be usable, and a dedicated SGD becomes necessary.

Dedicated Speech-Generating Devices (SGDs)

Dedicated SGDs are purpose-built communication devices pre-loaded with software and engineered to support multiple access methods as ALS progresses. The Tobii Dynavox TD I-Series (TD I-13, TD I-16) and the PRC-Saltillo Accent and NovaChat are the leading models on the US market. These devices run proprietary operating systems with software like TD Snap, Communicator 5, LAMP Words for Life, and Unity.

SGDs cost between $3,000 and $15,000. Medicare covers 80% of the cost for eligible patients who are not in hospice or a skilled nursing facility. Private insurance and Medicaid also provide coverage, though the approval process requires a clinician prescription and detailed documentation. For a broader look at daily living aids that complement communication devices, check our roundup of adaptive equipment for ALS patients.

Voice banking pairs naturally with SGDs. Patients record their natural speech using tools like ModelTalker (free, web-based) or commercial voice-cloning services, and the recorded voice is synthesized through the SGD later. This lets the device speak with the patient’s own vocal quality rather than a generic text-to-speech voice.

Access Methods That Keep Working as ALS Progresses

ALS requires a device that can switch access methods as motor function declines — starting with touch, moving to head-tracking, and ending with eye-gaze or partner-assisted scanning. Choosing a device that supports this transition is the single most important buying decision. Tobii Dynavox’s TD I-Series, for example, ships with eye-gaze capability built in, so the patient can use touch on day one and eye-gaze months later without buying new hardware.

The Speech Intelligibility Test is the standard clinical benchmark for timing an AAC referral. When speaking rates fall to 125 words per minute or lower, the National Institutes of Health recommends beginning the AAC evaluation process immediately. Delaying the referral reduces the patient’s ability to learn the new system as motor function continues to deteriorate.

How Do You Get an SGD Covered by Insurance?

Getting a speech-generating device through insurance follows a five-step process that starts with a clinical evaluation. Medicare covers 80% of the roughly $15,000 device cost for eligible patients who are not enrolled in hospice or a skilled nursing facility — a common misconception is that Medicare denies all SGD claims, but the exclusion is specific to those two settings only.

1. Evaluation. Schedule an assessment with a speech-language pathologist, neurologist, or primary care doctor who understands AAC needs.
2. Prescription. The clinician documents medical necessity, matches the device to the patient’s motor and cognitive abilities, and writes a formal prescription.
3. Funding submission. The clinician submits the prescription and supporting documentation to Medicare, Medicaid, or private insurance. Device trials are often arranged before the final purchase.
4. Customization. The device is configured with the patient and care circle — vocabulary sets, access method calibration, and voice integration are all set up during this step.
5. Ongoing support. The clinician monitors the patient’s changing needs and adapts the device settings as ALS progresses.

A device trial is worth requesting early. Many patients test two or three models before settling on one, and insurance will often cover the trial period. Tobii Dynavox and PRC-Saltillo both offer trial programs through their clinical partners.

Voice Banking Lets You Keep Your Own Voice

Voice banking records a patient’s natural speech so it can be synthesized later through an SGD. ModelTalker is a free, web-based tool that walks users through recording sentences over several sessions. Commercial voice-cloning services offer higher quality and more natural results but require careful review of data privacy and consent terms.

The recorded voice pairs with most dedicated SGDs. Patients should start voice banking as early as possible, ideally while their speech is still clear, because the recording quality depends on vocal clarity at the time of recording. The ALS Association recommends beginning the voice banking process immediately after diagnosis.

Are Brain-Computer Interfaces Ready Yet?

Brain-computer interfaces like the Connexus BCI are in clinical trials and not commercially available. These devices use an implanted chip that interprets neural signals and converts them to text or synthesized speech. The technology is promising for patients who lose all voluntary movement, including eye control, but it remains a research tool today.

No insurance plan covers BCIs, and no manufacturer offers them for sale. Patients interested in accessing BCI technology should search for active clinical trials through the NIH Clinical Trials database or their ALS clinic’s research coordinator. For current communication needs, tried-and-tested SGDs remain the reliable option.

Choosing the Right Communication Device

The right device is the one that works today and will still work six months from now. Start with low-tech tools during the evaluation period. Move to a tablet-based AAC app if hand control remains strong and insurance approval for an SGD will take weeks. Pursue a dedicated SGD with eye-gaze capability as the primary long-term solution, because it handles every access method that ALS will require.

Three decisions determine the outcome: selecting a device that supports multiple access methods, initiating the insurance process before the patient needs the device, and starting voice banking immediately. Families who act on all three give the patient the best chance of maintaining clear, natural communication throughout the disease.